L-type Calcium Channel Protein

Migration, Crosslink

📖

L-type Calcium Channel Protein

active

wiki page Created: 2026-04-02T07:19:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-cav1-2-protein

📖 Wiki Page

protein1470 wordssynced 2026-04-02

L-type Calcium Channel Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">L-type Calcium Channel Protein</th>
</tr>
<tr>
<td class="label">L-type Calcium Channel</td>
<td>L-type Calcium Channel Protein</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Transmembrane segments</td>
<td>24 segments (6 per domain)</td>
</tr>
<tr>
<td class="label">Selectivity filter</td>
<td>EEEE motif (positions 1394-1397)</td>
</tr>
<tr>
<td class="label">Voltage sensor</td>
<td>Positively charged S4 segments</td>
</tr>
<tr>
<td class="label">C-terminal tail</td>
<td>Multiple regulatory domains (CaM, CaMKII)</td>
</tr>
<tr>
<td class="label">Molecular weight</td>
<td>~250 kDa for α1 subunit</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Nifedipine</td>
<td>Clinical trial</td>
</tr>
<tr>
<td class="label">Isradipine</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Cav1.3-selective</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Allosteric modulators</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Class</td>
</tr>
<tr>
<td class="label">Nifedipine</td>
<td>Dihydropyridine</td>
</tr>
<tr>
<td class="label">Amlodipine</td>
<td>Dihydropyridine</td>
</tr>
<tr>
<td class="label">**Nicardip

...

L-type Calcium Channel Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">L-type Calcium Channel Protein</th>
</tr>
<tr>
<td class="label">L-type Calcium Channel</td>
<td>L-type Calcium Channel Protein</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Transmembrane segments</td>
<td>24 segments (6 per domain)</td>
</tr>
<tr>
<td class="label">Selectivity filter</td>
<td>EEEE motif (positions 1394-1397)</td>
</tr>
<tr>
<td class="label">Voltage sensor</td>
<td>Positively charged S4 segments</td>
</tr>
<tr>
<td class="label">C-terminal tail</td>
<td>Multiple regulatory domains (CaM, CaMKII)</td>
</tr>
<tr>
<td class="label">Molecular weight</td>
<td>~250 kDa for α1 subunit</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Nifedipine</td>
<td>Clinical trial</td>
</tr>
<tr>
<td class="label">Isradipine</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Cav1.3-selective</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Allosteric modulators</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Class</td>
</tr>
<tr>
<td class="label">Nifedipine</td>
<td>Dihydropyridine</td>
</tr>
<tr>
<td class="label">Amlodipine</td>
<td>Dihydropyridine</td>
</tr>
<tr>
<td class="label">Nicardipine</td>
<td>Dihydropyridine</td>
</tr>
<tr>
<td class="label">Verapamil</td>
<td>Phenylalkylamine</td>
</tr>
<tr>
<td class="label">Diltiazem</td>
<td>Benzothiazepine</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">171 edges</a></td>
</tr>
</table>

L-type calcium channels (LTCCs) are voltage-gated calcium channels that mediate calcium influx in response to membrane depolarization, playing critical roles in neuronal signaling, gene expression, synaptic plasticity, and cellular survival. The Cav1.2 channel, encoded by the CACNA1C gene, is the predominant L-type calcium channel in the brain and is central to the calcium hypothesis of neurodegenerative diseases[@berridge2021].

Cav1.2 channels are among the most extensively studied ion channels in the context of Alzheimer's disease (AD) and Parkinson's disease (PD) due to their central role in calcium dysregulation—a hallmark feature of neurodegeneration[@stanika2019].

Overview

L-type Calcium Channel Protein (Cav1.2) is a 2,373 amino acid, 248.6 kDa voltage-gated calcium channel localized to the cell membrane. It belongs to the Cav1 (L-type) channel family and is composed of a pore-forming α1C subunit (CACNA1C) along with auxiliary β and α2δ subunits[@zhao2020].

Dysregulation of Cav1.2 function contributes to the pathogenesis of Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders through effects on synaptic plasticity, calcium homeostasis, mitochondrial function, and cellular stress response. Cav1.2 is a major therapeutic target for neuroprotection in neurodegeneration[@zamponi2015].

Structure

Channel Architecture

Cav1.2 is a heteromultimeric complex consisting of:

α1C subunit (Cav1.2) - The pore-forming transmembrane protein

Four homologous domains (I-IV), each with 6 transmembrane segments
Voltage sensor in segment S4
Selectivity filter with the signature EEEE motif
C-terminal domain with multiple regulatory sites

β subunit (β1-β4) - Regulatory auxiliary subunit

Modulates channel trafficking and gating
Tissue-specific expression patterns

α2δ subunit (α2δ1-α2δ4) - Trafficking and modulatory subunit

Facilitates channel insertion into the membrane
Alters gating properties

γ subunit (optional) - Modulatory subunit

Tissue-specific auxiliary component

Key Structural Features

Post-translational Modifications

Phosphorylation by PKA, PKC, CaMKII
Glycosylation of extracellular domains
Palmitoylation of C-terminal regions
Ubiquitination for degradation[@simms2014]

Normal Function

Calcium Influx

Cav1.2 channels open in response to membrane depolarization, allowing Ca2+ influx:

Activation voltage: -40 to -30 mV (relatively positive)
Current type: Long-lasting (L-type), slow inactivation
Conductance: High-voltage activated (HVA)
Ion selectivity: High preference for Ca2+ over Na+

Key Physiological Roles

Synaptic Plasticity

Dendritic calcium influx: Triggers Ca2+-dependent signaling cascades
Gene expression: Activates CREB-mediated transcription
[Long-term potentiation](/mechanisms/long-term-potentiation) (LTP): Involved in some forms of synaptic strengthening
Long-term depression (LTD): Participates in synaptic weakening

Neuronal Excitability

Dendritic spikes: Contributes to back-propagating action potentials
Calcium electrogenesis: Generates dendritic Ca2+ spikes
Integration: Modulates synaptic integration in dendrites

Gene Regulation

Ca2+-dependent transcription: Activates calcineurin, CaMKIV, CREB
Activity-dependent plasticity: Links neuronal activity to gene expression
Homeostatic responses: Adjusts neuronal properties to activity levels

Other Tissues

Cardiac muscle: Primary calcium entry pathway for contraction
Smooth muscle: Vascular tone regulation
Endocrine cells: Hormone secretion
Auditory system (Cav1.3): Cochlear function[@ghosh1995]

Role in Alzheimer's Disease

Calcium Dysregulation Hypothesis

The "calcium hypothesis" of AD proposes that dysregulated calcium signaling is a central mechanism in disease pathogenesis[@berridge2021]. Cav1.2 channels contribute to this through multiple mechanisms:

Amyloid-β Effects

Direct interaction: [Aβ](/proteins/amyloid-beta) peptides can modulate channel function
Membrane disruption: Aβ alters lipid environment affecting channels
Increased influx: Enhanced Ca2+ entry through affected [neurons](/entities/neurons)
Synaptic dysfunction: Impaired plasticity due to Ca2+ dysregulation

Excitotoxicity

[NMDA receptor](/entities/nmda-receptor) cross-talk: L-type channels compensate for NMDAR activity
Excessive influx: Pathological Ca2+ overload
Downstream activation: Calpain, caspase activation
Mitochondrial dysfunction: Ca2+ overload of mitochondria

Tau Pathology

Ca2+ dysregulation: [Tau](/proteins/tau) pathology affects channel function
Homeostatic disruption: Loss of tau-mediated buffering
Dendritic spine loss: Ca2+-dependent spine elimination

Therapeutic Implications

Clinical trials of dihydropyridine L-type blockers (e.g., nimodipine, nifedipine) have shown mixed results, with ongoing research into more targeted approaches[@anekonda2015].

Role in Parkinson's Disease

Selective Vulnerability of Dopaminergic Neurons

Midbrain dopaminergic neurons, particularly those in the substantia nigra pars compacta (SNc), show early dysfunction of Cav1.2/Cav1.3 channels:

Cav1.3 Role

Lower voltage activation: Cav1.3 activates at more negative potentials
Pacemaker activity: Drives autonomous firing of SNc neurons
Calcium burden: Continuous activity leads to high Ca2+ influx
Mitochondrial stress: High energy demands for Ca2+ handling

Mechanisms of Vulnerability

Calcium overload: Chronic Ca2+ influx overwhelms buffering

Mitochondrial dysfunction: Impaired Ca2+ sequestration

Oxidative stress: Increased [reactive oxygen species](/entities/reactive-oxygen-species)

Neuroinflammation: Activated [microglia](/cell-types/microglia-neuroinflammation) respond to Ca2+ dysregulation

Therapeutic Targeting

Isradipine, a Cav1.2/Cav1.3 blocker, has been investigated in PD clinical trials:

Rationale: Reduce Ca2+ burden in dopaminergic neurons
Challenge: Must preserve normal neuronal function
Outcome: Clinical trials showed modest effects[@surmeier2017]

Role in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

Motor neuron hyperexcitability: Altered L-type channel function
Excitotoxicity: Enhanced Ca2+ entry
Therapeutic potential: Channel modulators under investigation

Timothy Syndrome

CACNA1C mutations: Cause severe multisystem disorder
Neurological features: Autism, intellectual disability, seizures
Modeling: iPSC-derived neurons show altered Ca2+ dynamics

Psychiatric Disorders

Bipolar disorder: CACNA1C is a genome-wide significant risk gene
Schizophrenia: Some association with CACNA1C variants
Mechanism: Altered neuronal excitability and plasticity[@bigos2018]

Therapeutic Targeting

Approved Drugs

Investigational Approaches

State-dependent blockers: Preferentially bind open/inactivated states

Cav1.3-selective: Reduce cardiac side effects

Allosteric modulators: Different binding sites

Gene therapy: AAV-mediated delivery (experimental)

Channel openers: For cognitive enhancement

Challenges

[Blood-brain barrier](/entities/blood-brain-barrier): Many drugs have limited CNS penetration
Cardiac effects: L-type channels crucial for heart function
Narrow therapeutic window: Balancing efficacy and side effects
Channel compensatory mechanisms[@dolphin2023]

Key Publications

Calcium hypothesis of Alzheimer's disease (2021). Nat Rev Neurosci. PMID: 34017082(https://pubmed.ncbi.nlm.nih.gov/34017082/)

Cav1.2 and Cav1.3 in neuronal survival and death (2019). Cell Calcium. PMID: 31171369(https://pubmed.ncbi.nlm.nih.gov/31171369/)

Structure of voltage-gated calcium channels (2020). Nature. PMID: 32941613(https://pubmed.ncbi.nlm.nih.gov/32941613/)

L-type calcium channels in neurodegenerative diseases (2021). Pharmacol Rev. PMID: 33723085(https://pubmed.ncbi.nlm.nih.gov/33723085/)

Cav1.2 channelopathies in neurological disease (2019). Brain. PMID: 30715176(https://pubmed.ncbi.nlm.nih.gov/30715176/)

Calcium signaling in neuronal development and disease (2020). Dev Neurobiol. PMID: 31950596(https://pubmed.ncbi.nlm.nih.gov/31950596/)

L-type calcium channel blockers for Alzheimer's disease (2022). Alzheimers Dement. PMID: 35653325(https://pubmed.ncbi.nlm.nih.gov/35653325/)

Isradipine for Parkinson's disease (2018). Nat Rev Neurol. PMID: 29980753(https://pubmed.ncbi.nlm.nih.gov/29980753/)

CACNA1C and psychiatric disorders (2020). Mol Psychiatry. PMID: 32080385(https://pubmed.ncbi.nlm.nih.gov/32080385/)

Voltage-gated calcium channels as drug targets (2016). Mol Pharmacol. PMID: 27563058(https://pubmed.ncbi.nlm.nih.gov/27563058/)

External Links

[UniProt Q13936 (Cav1.2)](https://www.uniprot.org/uniprot/Q13936)
[NCBI Gene: CACNA1C](https://www.ncbi.nlm.nih.gov/gene/775)
[IUPHAR: L-type Calcium Channels](https://www.guidetopharmacology.org/GRID/FamilyIntroduction?familiar=&topfamily=Voltage-gated%20calcium%20channels&subfamily=L-type%20calcium%20channels)
[PDB: Cav1.2 Structure](https://www.rcsb.org/structure/6JP5)

Background

The study of L Type Calcium Channel Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Berridge MJ, Calcium hypothesis of Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34017082/)

[Stanika R, et al, Physiological and pathological functions of neuronal Cav1.2 and Cav1.3 calcium channels (2019)](https://pubmed.ncbi.nlm.nih.gov/31171369/)

[Zhao Y, et al, Cryo-EM structures of human voltage-gated calcium channel Cav1.2 and Cav1.3 (2020)](https://pubmed.ncbi.nlm.nih.gov/32941613/)

[Zamponi GW, et al, Targeting voltage-gated calcium channels in neurological and psychiatric diseases (2015)](https://pubmed.ncbi.nlm.nih.gov/25486083/)

[Simms BA, Zamponi GW, Neuronal voltage-gated calcium channel subtypes: does the subtype match the therapeutic target? Trends Pharmacol Sci (2014)](https://pubmed.ncbi.nlm.nih.gov/25017531/)

[Ghosh A, Greenberg ME, Calcium signaling in neurons: molecular mechanisms and cellular consequences (1995)](https://pubmed.ncbi.nlm.nih.gov/7716515/)

[Anekonda V, et al, L-type voltage-gated calcium channel blockade as a therapeutic strategy for Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25616651/)

[Surmeier DJ, et al, Calcium and Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/29980753/)

[Bigos KL, et al, Genetic variation in CACNA1C: from circuits to function (2018)](https://pubmed.ncbi.nlm.nih.gov/29559723/)

[Dolphin AC, Calcium channel auxiliary α2δ and β subunits: trafficking and therapeutic potential (2023)](https://pubmed.ncbi.nlm.nih.gov/36906765/)

📖 View canonical wiki page →

Related Entities

CAV12PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-cav1-2-protein
kg_node_id	CAV12PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-413d1a894b8e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-cav1-2-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

95%

Debates

0

Incoming

19

Outgoing

20

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

L-type Calcium Channel Protein

L-type Calcium Channel Protein

Introduction

L-type Calcium Channel Protein

Introduction

Overview

Structure

Channel Architecture

Key Structural Features

Post-translational Modifications

Normal Function

Calcium Influx

Key Physiological Roles

Synaptic Plasticity

Neuronal Excitability

Gene Regulation

Other Tissues

Role in Alzheimer's Disease

Calcium Dysregulation Hypothesis

Amyloid-β Effects

Excitotoxicity

Tau Pathology

Therapeutic Implications

Role in Parkinson's Disease

Selective Vulnerability of Dopaminergic Neurons

Cav1.3 Role

Mechanisms of Vulnerability

Therapeutic Targeting

Role in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

Timothy Syndrome

Psychiatric Disorders

Therapeutic Targeting

Approved Drugs

Investigational Approaches

Challenges

Key Publications

See Also

External Links

Background

References

💬 Discussion